Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

CGTX stock hub

Cognition Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

CGTXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

108.1M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

CGTX

In the news

Latest news · CGTX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.6P50 18.3P75 33.7

Trailing P/En/a

P25 15P50 23.3P75 38.5

ROEn/a

P25 -106.6P50 -46.9P75 -3.1

ROIC-112

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All CGTX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

160

Groups with data

Currency

USD

Showing 160 of 160 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001455365
Company name	Cognition Therapeutics, Inc.
Country	United States
Country code	US
Cusip	19243B102
Employees	14
Employees Change	-14%
Employees Change Percent	-50
Enterprise value	$71.9M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-10-08
Isin	US19243B1026
Last refreshed	2026-05-10
Market cap	$108.1M
Market cap category	Micro-Cap
Price	$1.21
Price currency	USD
Sector	Healthcare
Sic	2836
Symbol	CGTX
Website	https://www.cogrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-18.11%
P/B ratio	3.14x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-19.6M
Net Income Growth Quarters	6%
Net Income Growth Years	1%
Profit Per Employee	$-1.4M
Roa5y	-71.37
Roe5y	-86.63
ROIC	-112

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	241.42%
Cagr3y	-8.12%
EPS Growth Quarters	6
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	$36.8M
Debt	$638,000
Debt Equity	$0.02
Equity	$34.3M
Interest Coverage	-3,295.5
Net Cash	$36.2M
Net Cash By Market Cap	$33.46
Net Cash Growth	129.04%
Net Debt Equity	$-1.06
Tangible Book Value	$34.3M
Tangible Book Value Per Share	$0.39
WACC	14.14

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-70.27%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	241.13%
200-day SMA	1.41
3Y total return	-22.44%
50-day SMA	1.07
50-day SMA vs 200-day SMA	50under200
All Time High	13.8
All Time High Change	-91.23%
All Time High Date	2021-10-08
All Time Low	0.22
All Time Low Change	444.31%
All Time Low Date	2025-05-28
ATR	0.1
Beta	1.81
Beta1y	3.29
Beta2y	2.74
Ch YTD	-10.37
High	1.23
High52	3.83
High52 Date	2025-08-25
High52ch	-68.41%
Low	1.15
Low52	0.22
Low52 Date	2025-05-28
Low52ch	444.31%
Ma50ch	12.77%
Premarket Change Percent	1.72
Premarket Price	$1.18
Premarket Volume	22,244
Price vs 200-day SMA	-14.37%
RSI	54.33
RSI Monthly	45.05
RSI Weekly	49.76
Sharpe ratio	1.51x
Sortino ratio	2.75
Total Return	-70.27%
Tr YTD	-10.37
Tr1m	48.03%
Tr1w	-5.47%
Tr3m	14.15%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Count Top	1
Analyst Price Target Top	$4
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.07
Earnings Revenue Estimate	880,000x
Operating Income	$-42.8M
Price target	$3.33
Price Target Change	$175
Price Target Change Top	$231

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	82,305,187%
Float Percent	92.11%
Shares Insiders	1.17%
Shares Institutions	17.64%
Shares Out	89,353,773
Shares Qo Q	0.66%
Shares Yo Y	70.27%
Short Float	8.89%
Short Ratio	4.84
Short Shares	8.19

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	1,089,522.3x
Bv Per Share	0.39
Ch1m	48.03
Ch1w	-5.47
Ch1y	241.1
Ch3m	14.15
Ch3y	-22.44
Ch6m	-27.11
Change	4.31%
Change From Open	3.42
Close	1.16
Days Gap	0.86
Depreciation Amortization	18,250
Dollar Volume	839,642
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-42.8M
EBITDA	$-42.8M
EPS	$-0.25
F Score	0
Fiscal Year End	December
Founded	2,007
Ipr	-89.92
Iprfo	-90.04
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-26
Ma150	1.35
Ma150ch	-10.1%
Ma20	1.19
Ma20ch	1.42%
Next Earnings Date	2026-08-06
Open	1.17
Optionable	No
Position In Range	74.03
Post Close	1.21
Postmarket Change Percent	1.65
Postmarket Price	$1.23
Pre Close	1.16
Price Date	2026-05-08
Ptbv Ratio	3.15
Relative Volume	0.64x
Tr6m	-27.11%
Us State	New York
Volume	693,919

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does CGTX pay a dividend?

Capital-return profile for this ticker.

Performance

CGTX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns CGTX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+17.6%

Float: +92.1% of shares outstanding

Insider ownership

+1.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

CGTX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

54.3

Neutral momentum band

Price vs 200-day MA

-14.4%

50/200-day relationship not available

Beta (5Y)

1.81

More volatile than the market

Sharpe ratio

1.51

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About CGTX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current CGTX stock rating?

Cognition Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CGTX analysis?

The full report lives at /stocks/CGTX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for CGTX?

The latest report frames CGTX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the CGTX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.